Trial Profile

Effects of extended exposure to lixisenatide on gastric emptying and postprandial glycaemia in patients with type 2 diabetes treated with metformin

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lixisenatide (Primary) ; Paracetamol
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

25 Sep 2020 Results assessing paracetamol absorption and gastric emptying parameters in patients with type 2 diabetes presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
29 May 2020 Results assessing whether prolonged use of a "short-acting" GLP-1 receptor agonist, lixisenatide, achieves sustained slowing of gastric emptying and reduction in postprandial glycemia published in the Diabetes Care
19 Mar 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com